Monthly Archives: August 2011

ECCA and EDMA advance the EU health literacy debate

As part of the 2011 European Cervical Cancer Week, EDMA, the European Diagnostic Manufacturers Association and the ECCA, the European Cervical Cancer Association jointly organised the “Better Health Literacy for Better Health in Europe” dinner debate. EDMA, the European Diagnostic … Continue reading

Posted in Uncategorized | Leave a comment

Faked cancer lands British man in jail

A British father who faked a terminal cancer to his family and friends to ???con??™ them out of cash, is beginning a 20 month jail sentence today. Simon Swift, 39, from Rugby in Warwickshire, central England started by telling his … Continue reading

Posted in Uncategorized | Leave a comment

Survival following transplant surgery for liver cancer not impacted by HIV-positive status

French researchers determined that infection with human immunodeficiency virus (HIV) impaired results of transplant surgery for liver cancer, with more HIV infected patients dropping off the transplantation wait list. The team found that overall survival and recurrence-free survival was not … Continue reading

Posted in Uncategorized | Leave a comment

Johnson & Johnson fourth quarter sales decreases 5.5% to $15.6 billion

Johnson & Johnson today announced sales of $15.6 billion for the fourth quarter of 2010, a decrease of 5.5% as compared to the fourth quarter of 2009. Operational sales declined 5.1% and the negative impact of currency was 0.4%. Domestic … Continue reading

Posted in Uncategorized | Leave a comment

FDA grants BioSante Orphan Drug designation for Melanoma Cancer Vaccine

BioSante Pharmaceuticals, Inc. today announced the receipt of Orphan Drug designation for its Melanoma Cancer Vaccine in the treatment of stage IIb to IV melanoma, from the FDA’s Office of Orphan Products Development. Melanoma is the most deadly form of … Continue reading

Posted in Uncategorized | Leave a comment

Emergent BioSolutions initiates TRU-016 Phase Ib/II study for chronic lymphocytic leukemia

Emergent BioSolutions Inc. today announced the initiation of a Phase Ib/II study (16201) of TRU-016 for chronic lymphocytic leukemia (CLL). TRU-016 is a CD37-directed Small Modular ImmunoPharmaceutical (SMIP?„?) protein therapeutic in development for the treatment of B-cell malignancies. TRU-016 is … Continue reading

Posted in Uncategorized | Leave a comment

Realignment with participants' interest important for future of genomic research

Obtaining consent for genetic studies can be an opportunity for researchers to foster respectful engagement with participants, not merely to mitigate legal risk. This shift is proposed in a policy forum appearing tomorrow, Jan. 21, in Science, the journal of … Continue reading

Posted in Uncategorized | Leave a comment